Pharma a bright spot in CSL's "reset" year

CSL's pharmaceuticals were a bright spot in its 2026 earnings, which saw it fall into loss after taking huge impairments from Vifor.

"We've been able to maintain momentum to stabilise the company's performance, restore the cadence and focus of the leadership team, and start to deliver results," CSL Interim CEO, Gordon Naylor, told the earnings call.

"Considerable work remains, but we are making progress. FY26 has been a reset year for CSL. The actions that put us back on the path to sustainable growth started well before my appointment, and have been delivered with intention and urgency."

To see the whole article please log in.

James Quintana Pearce

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here